Industry Deep-Dive: Treatment Planning Software vs. Advanced Image Processing Software for Precision Oncology
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Treatment Planning Systems and Advanced Image Processing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Treatment Planning Systems and Advanced Image Processing market, including market size, share, demand, industry development status, and forecasts for the next few years.
Core User Pain Point & Solution Direction: Radiation oncologists and medical physicists face a critical precision challenge: delivering high doses of radiation to tumors while minimizing exposure to surrounding healthy organs requires complex dose calculation, optimization, and image verification. Manual contouring is time-consuming (2-4 hours per patient), inconsistent between physicians, and difficult to adapt for daily anatomical changes. Treatment planning systems (TPS) and advanced image processing software solve this through computerized planning and AI-assisted tools. TPS enables 3D dose calculation, inverse planning, and optimization for IMRT, VMAT, SBRT, and proton therapy. Advanced image processing software provides image registration (CT-MRI fusion, multi-modality alignment), deformable registration for adaptive radiotherapy, and AI-driven auto-segmentation (organ-at-risk contouring). For radiation oncology departments, these systems reduce planning time (60-80% reduction with AI contouring), improve plan quality (better target coverage, OAR sparing), and enable adaptive radiotherapy (daily plan adaptation based on patient anatomy changes).
Global Market Size & Growth Trajectory
The global market for Treatment Planning Systems and Advanced Image Processing was estimated to be worth US2,400millionin2025andisprojectedtoreachUS2,400millionin2025andisprojectedtoreachUS 3,600 million, growing at a CAGR of 6.0% from 2026 to 2032. Market growth is driven by increasing global cancer incidence (estimated 20 million new cases annually by 2030), adoption of advanced radiotherapy techniques (IMRT, VMAT, SBRT, SRS, proton therapy), AI integration (auto-segmentation, automated planning), and adaptive radiotherapy (daily plan adaptation).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5983896/treatment-planning-systems-and-advanced-lmage-processing
Market Share & Competitive Landscape
The market features a highly consolidated landscape with radiation oncology equipment leaders:
- Varian Medical Systems (Siemens Healthineers) (US/Germany) – Global leader, approximately 35% market share. Eclipse TPS (including RapidPlan, Ethos AI). Strong integrated hardware-software (TrueBeam, Halcyon).
- Elekta (Sweden) – Second-largest, approximately 20% share. Monaco TPS, Philips Pinnacle (Elekta-owned). Strong in MR-linac (Unity) and adaptive radiotherapy.
- Koninklijke Philips NV (Netherlands) – Approximately 12% share. Pinnacle TPS, MR-linac planning, image processing (IntelliSpace Portal).
- RaySearch Laboratories (Sweden) – Approximately 8% share. RayStation TPS (independent, multi-vendor). Strong in proton therapy planning and adaptive RT.
- Accuray Incorporated (US) – Approximately 5% share. TomoTherapy TPS (Precision), CyberKnife planning.
- Brainlab, MIM Software, Viewray, DOSIsoft, Prowess – Regional and specialist players.
The top three (Varian, Elekta, Philips) account for approximately 67% of global market share.
Type Segmentation
- Treatment Planning Software (70% share) – Core TPS for dose calculation, optimization, plan evaluation. Includes IMRT/VMAT, SBRT/SRS, proton therapy, brachytherapy modules. 5.5% CAGR.
- Advanced Image Processing Software (30% share) – Fastest-growing segment (8.5% CAGR). AI-driven auto-segmentation (organs at risk, target volumes), deformable image registration (adaptive RT), multi-modality fusion (CT-MRI-PET), motion management (4D CT).
Application Segmentation
- Adaptive Radiotherapy (45% share) – Largest and fastest-growing segment (7.5% CAGR). Daily or weekly plan adaptation based on anatomy changes (weight loss, tumor shrinkage, organ filling). Requires deformable registration and re-optimization.
- Image Registration Verification (35% share) – 5.8% CAGR. CT-CBCT alignment for daily setup verification, multi-modality fusion for target definition, longitudinal registration for treatment response assessment.
- Others (20% share) – Dose accumulation (accumulating dose across fractions), quality assurance tools, remote plan review, clinical trial planning.
Technical Deep-Dive: TPS and Image Processing Capabilities
| Feature | Standard TPS | Advanced TPS + AI |
|---|---|---|
| Dose calculation algorithm | Pencil beam, collapsed cone (2-5 min) | Monte Carlo, Acuros XB (5-15 min, more accurate) |
| Inverse planning (IMRT/VMAT) | Manual trade-offs, iterative | Multi-criteria optimization (MCO), knowledge-based planning (RapidPlan) |
| Auto-segmentation | Atlas-based (limited anatomy, 10-20 min) | Deep learning (all OARs + targets, 1-2 minutes) |
| Deformable registration | Limited (organ motion, 5-10 min) | Advanced (daily adaptation, 1-2 min) |
| Adaptive radiotherapy | Offline (re-plan weekly) | Online (daily adaptation, 10-15 minutes) |
| Plan quality | Operator-dependent | AI-optimized, consistent |
Recent Technical Barrier & Breakthrough (Q1 2025) – A persistent challenge in adaptive radiotherapy has been the time required for daily replanning (30-60 minutes), limiting clinical adoption. Varian introduced “Ethos” AI-driven online adaptive radiotherapy with HD(High Definition) physics engine, reducing re-planning time to 10-15 minutes. The system automatically contours targets and OARs on daily CBCT, re-optimizes the plan, and performs QA (quality assurance) before treatment delivery. Over 500 systems installed globally by 2025, enabling routine daily adaptation for prostate, bladder, cervical, and pancreatic cancers.
Typical User Case (Q2 2025) – A US academic cancer center (anonymous, 8 linacs, 100+ patients/day) implemented Elekta Monaco TPS with AI-driven auto-segmentation (MIM Software). Results: OAR contouring time reduced from 45 minutes to 5 minutes per patient (8x faster), inter-physician contour variation reduced 65% (standardized atlases), and adaptive radiotherapy (weekly replanning) increased from 5% to 30% of patients. Annual physics and dosimetry FTE savings: 3.0 positions (US$ 450,000).
Exclusive Observation: AI Revolutionizing Treatment Planning
Artificial intelligence is transforming TPS and image processing across three domains:
1. AI Auto-Segmentation (Contouring):
- Deep learning models (U-Net, nnU-Net) trained on thousands of expert-contoured CT/MRI datasets.
- Organs at risk (heart, lungs, esophagus, spinal cord, parotids, rectum, bladder): Dice similarity coefficient (DSC) >0.85-0.95 (near-expert level).
- Target volumes (GTV, CTV, PTV): More challenging (tumor boundaries), but AI provides excellent starting point for physician editing.
- Time savings: 60-80% reduction in contouring time.
2. Knowledge-Based Planning (KBP):
- Model trained on prior high-quality clinical plans.
- Predicts achievable dose-volume histograms (DVHs) for OARs based on patient anatomy.
- Provides planning target, reduces trial-and-error, improves plan consistency.
- Outcome: 30-50% reduction in planning time, 10-20% improvement in OAR sparing.
3. Automated Machine Learning (AutoML) for Plan Optimization:
- Iterative optimization without manual trade-off weights.
- Multi-criteria optimization (MCO) exploring Pareto-optimal plans.
- Clinical decision support: recommends best plan based on physician preferences.
Market impact: AI features are becoming standard in new TPS purchases (80%+ of systems sold in 2025 include AI auto-segmentation, 50%+ include KBP). Smaller vendors (RaySearch, Brainlab, MIM) differentiate through AI capabilities, challenging Varian/Elekta dominance.
Industry Segmentation: Medical Software Development
Treatment planning system development is high-complexity medical software engineering with significant regulatory barriers (FDA Class II, CE Mark MDR). Key components: (1) dose calculation engine (Monte Carlo, collapsed cone convolution, Acuros, PB), (2) optimization algorithms (inverse planning for IMRT/VMAT), (3) DICOM-RT import/export (images, structures, dose, plans), (4) image processing (registration, segmentation, fusion), (5) user interface (physician-centric, workflow-driven). Barriers include (1) regulatory approval (FDA 510(k) or De Novo, 12-24 months), (2) physics validation (TG-53, TG-119, clinical trials), (3) interoperability with multiple vendor linacs and imaging systems, (4) R&D cost (US$ 50-200 million for a modern TPS).
Cost structure (TPS software license, US$ 50,000-150,000 per linac/year):
| Component | Percentage |
|---|---|
| Software development (R&D, physics, engineering) | 40-50% |
| Regulatory compliance (FDA, CE, NMPA) | 10-15% |
| Sales and marketing | 10-15% |
| Installation and training | 10-15% |
| Maintenance and support (annual) | 10-15% |
| Margin (Varian, Elekta, Philips) | 20-30% |
Additional Market Dynamics: The market faces challenges from (1) open-source TPS (limited clinical adoption), (2) cloud-based TPS (lower upfront cost, but data security and workflow concerns), (3) MRI-guided radiotherapy (new planning requirements, but Philips/Elekta competitive), (4) proton therapy (requires specialized planning, RaySearch dominant). However, the combination of precision radiotherapy adoption, AI integration, and global cancer burden positions the treatment planning systems and advanced image processing market for sustained 5-7% annual growth through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
